Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Type

Type

Guidance programme

Advice programme

Showing 1 to 19 of 19

TitleReference numberPublishedLast updated
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapiesTA872
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin geneHST22
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myelomaTA870
LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosisMIB317
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal)TA867
Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal)TA869
Urinary tract infections in adultsQS90
Vutrisiran for treating hereditary transthyretin-related amyloidosisTA868
Ambu aScope 4 RhinoLaryngo for visualising upper airways during rhinolaryngoscopyMIB316
Antenatal careQS22
Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and managementNG231
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinomaTA865
Regorafenib for previously treated metastatic colorectal cancerTA866
Transvenous obliteration for gastric varicesIPG751
Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancerIPG752
Upadacitinib for treating active non-radiographic axial spondyloarthritisTA861
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatmentsTA862
Somatrogon for treating growth disturbance in children and young people aged 3 years and overTA863
Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predictedTA864

Results per page

  1. 10
  2. 25
  3. 50
  4. All